Eikon Therapeutics presents early PARP1 and WRN inhibitor data at ESMO 2026
Eikon Therapeutics disclosed Phase 1/2 results for its PARP1 inhibitors EIK1003 and EIK1004 and the WRN helicase inhibitor EIK1005 at the 2026 European Society for Medical Oncology meeting. EIK1003 monotherapy showed a 14.3% objective response rate (ORR) and higher activity in PARP‑naïve patients, while combinations with abiraterone and paclitaxel yielded ORRs of 20.8% and 26.4% respectively. EIK1004 monotherapy achieved a 12.1% ORR with minimal grade 3+ hematologic toxicity, and EIK1005 produced a partial response in the first patient treated. Additional data are slated for release in 2027.
Why it matters
The company expects the forthcoming 2027 data to clarify the registrational potential of these programs, which could affect future valuation and partnership opportunities.
Key facts
- 1EIK1003 monotherapy ORR was 14.3% among 49 efficacy‑evaluable participants. tradingview.com
- 2EIK1003 combined with paclitaxel showed an ORR of 26.4%. tradingview.com
- 3EIK1003 combined with abiraterone yielded an ORR of 20.8% and a clinical benefit rate of 58.3% lasting ≥18 weeks. tradingview.com
- 4EIK1004 monotherapy ORR was 12.1% among 58 participants. tradingview.com
- 5EIK1005 produced a partial response in the first patient treated. tradingview.com
- 6Safety data cutoff for all cohorts was July 13 2026. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.